These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 30721156)

  • 1. RABL6A inhibits tumor-suppressive PP2A/AKT signaling to drive pancreatic neuroendocrine tumor growth.
    Umesalma S; Kaemmer CA; Kohlmeyer JL; Letney B; Schab AM; Reilly JA; Sheehy RM; Hagen J; Tiwari N; Zhan F; Leidinger MR; O'Dorisio TM; Dillon J; Merrill RA; Meyerholz DK; Perl AL; Brown BJ; Braun TA; Scott AT; Ginader T; Taghiyev AF; Zamba GK; Howe JR; Strack S; Bellizzi AM; Narla G; Darbro BW; Quelle FW; Quelle DE
    J Clin Invest; 2019 Mar; 129(4):1641-1653. PubMed ID: 30721156
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RABL6A promotes G1-S phase progression and pancreatic neuroendocrine tumor cell proliferation in an Rb1-dependent manner.
    Hagen J; Muniz VP; Falls KC; Reed SM; Taghiyev AF; Quelle FW; Gourronc FA; Klingelhutz AJ; Major HJ; Askeland RW; Sherman SK; O'Dorisio TM; Bellizzi AM; Howe JR; Darbro BW; Quelle DE
    Cancer Res; 2014 Nov; 74(22):6661-70. PubMed ID: 25273089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RABL6A Is an Essential Driver of MPNSTs that Negatively Regulates the RB1 Pathway and Sensitizes Tumor Cells to CDK4/6 Inhibitors.
    Kohlmeyer JL; Kaemmer CA; Pulliam C; Maharjan CK; Samayoa AM; Major HJ; Cornick KE; Knepper-Adrian V; Khanna R; Sieren JC; Leidinger MR; Meyerholz DK; Zamba KD; Weimer JM; Dodd RD; Darbro BW; Tanas MR; Quelle DE
    Clin Cancer Res; 2020 Jun; 26(12):2997-3011. PubMed ID: 32086342
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Knockdown of Yin Yang 1 enhances anticancer effects of cisplatin through protein phosphatase 2A-mediated T308 dephosphorylation of AKT.
    Zhao L; Li R; Gan YH
    Cell Death Dis; 2018 Jul; 9(7):747. PubMed ID: 29970878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of PP2A and Inhibition of mTOR Synergistically Reduce MYC Signaling and Decrease Tumor Growth in Pancreatic Ductal Adenocarcinoma.
    Allen-Petersen BL; Risom T; Feng Z; Wang Z; Jenny ZP; Thoma MC; Pelz KR; Morton JP; Sansom OJ; Lopez CD; Sheppard B; Christensen DJ; Ohlmeyer M; Narla G; Sears RC
    Cancer Res; 2019 Jan; 79(1):209-219. PubMed ID: 30389701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. STK33 Promotes the Growth and Progression of Human Pancreatic Neuroendocrine Tumour via Activation of the PI3K/AKT/mTOR Pathway.
    Zhou B; Xiang J; Zhan C; Liu J; Yan S
    Neuroendocrinology; 2020; 110(3-4):307-320. PubMed ID: 31261148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ciliary transport regulates PDGF-AA/αα signaling via elevated mammalian target of rapamycin signaling and diminished PP2A activity.
    Umberger NL; Caspary T
    Mol Biol Cell; 2015 Jan; 26(2):350-8. PubMed ID: 25392303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RABL6A Promotes Pancreatic Neuroendocrine Tumor Angiogenesis and Progression In Vivo.
    Maharjan CK; Umesalma S; Kaemmer CA; Muniz VP; Bauchle C; Mott SL; Zamba KD; Breheny P; Leidinger MR; Darbro BW; Stephens SB; Meyerholz DK; Quelle DE
    Biomedicines; 2021 Jun; 9(6):. PubMed ID: 34199469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. mTOR kinase inhibition reduces tissue factor expression and growth of pancreatic neuroendocrine tumors.
    Lewis CS; Elnakat Thomas H; Orr-Asman MA; Green LC; Boody RE; Matiash K; Karve A; Hisada YM; Davis HW; Qi X; Mercer CA; Lucas FV; Aronow BJ; Mackman N; Versteeg HH; Bogdanov VY
    J Thromb Haemost; 2019 Jan; 17(1):169-182. PubMed ID: 30472780
    [TBL] [Abstract][Full Text] [Related]  

  • 10. (+)-Cyanidan-3-ol inhibits epidermoid squamous cell carcinoma growth via inhibiting AKT/mTOR signaling through modulating CIP2A-PP2A axis.
    Monga J; Suthar SK; Rohila D; Joseph A; Chauhan CS; Sharma M
    Phytomedicine; 2022 Jul; 101():154116. PubMed ID: 35525235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PP2A inhibitor SET promotes mTORC1 and Bmi1 signaling through Akt activation and maintains the colony-formation ability of cancer cells.
    Kohyanagi N; Kitamura N; Ikeda S; Shibutani S; Sato K; Ohama T
    J Biol Chem; 2024 Jan; 300(1):105584. PubMed ID: 38141761
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activation of tumor suppressor protein PP2A inhibits KRAS-driven tumor growth.
    Sangodkar J; Perl A; Tohme R; Kiselar J; Kastrinsky DB; Zaware N; Izadmehr S; Mazhar S; Wiredja DD; O'Connor CM; Hoon D; Dhawan NS; Schlatzer D; Yao S; Leonard D; Borczuk AC; Gokulrangan G; Wang L; Svenson E; Farrington CC; Yuan E; Avelar RA; Stachnik A; Smith B; Gidwani V; Giannini HM; McQuaid D; McClinch K; Wang Z; Levine AC; Sears RC; Chen EY; Duan Q; Datt M; Haider S; Ma'ayan A; DiFeo A; Sharma N; Galsky MD; Brautigan DL; Ioannou YA; Xu W; Chance MR; Ohlmeyer M; Narla G
    J Clin Invest; 2017 Jun; 127(6):2081-2090. PubMed ID: 28504649
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduced menin expression impairs rapamycin effects as evidenced by an increase in mTORC2 signaling and cell migration.
    Razmara M; Monazzam A; Skogseid B
    Cell Commun Signal; 2018 Oct; 16(1):64. PubMed ID: 30285764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Growth of the pancreatic cancer cell line PANC-1 is inhibited by protein phosphatase 2A inhibitors through overactivation of the c-Jun N-terminal kinase pathway.
    Li W; Chen Z; Gong FR; Zong Y; Chen K; Li DM; Yin H; Duan WM; Miao Y; Tao M; Han X; Xu ZK
    Eur J Cancer; 2011 Nov; 47(17):2654-64. PubMed ID: 21958460
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cucurmosin induces apoptosis of BxPC-3 human pancreatic cancer cells via inactivation of the EGFR signaling pathway.
    Zhang B; Huang H; Xie J; Xu C; Chen M; Wang C; Yang A; Yin Q
    Oncol Rep; 2012 Mar; 27(3):891-7. PubMed ID: 22139427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RABL6A, a novel RAB-like protein, controls centrosome amplification and chromosome instability in primary fibroblasts.
    Zhang X; Hagen J; Muniz VP; Smith T; Coombs GS; Eischen CM; Mackie DI; Roman DL; Van Rheeden R; Darbro B; Tompkins VS; Quelle DE
    PLoS One; 2013; 8(11):e80228. PubMed ID: 24282525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiple pathways regulated by the tumor suppressor PP2A in transformation.
    Westermarck J; Hahn WC
    Trends Mol Med; 2008 Apr; 14(4):152-60. PubMed ID: 18329957
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disruption and inactivation of the PP2A complex promotes the proliferation and angiogenesis of hemangioma endothelial cells through activating AKT and ERK.
    Xie F; Bao X; Yu J; Chen W; Wang L; Zhang Z; Xu Q
    Oncotarget; 2015 Sep; 6(28):25660-76. PubMed ID: 26308070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protein phosphatase 2A activation as a therapeutic strategy for managing MYC-driven cancers.
    Farrington CC; Yuan E; Mazhar S; Izadmehr S; Hurst L; Allen-Petersen BL; Janghorban M; Chung E; Wolczanski G; Galsky M; Sears R; Sangodkar J; Narla G
    J Biol Chem; 2020 Jan; 295(3):757-770. PubMed ID: 31822503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alisertib induces cell cycle arrest and autophagy and suppresses epithelial-to-mesenchymal transition involving PI3K/Akt/mTOR and sirtuin 1-mediated signaling pathways in human pancreatic cancer cells.
    Wang F; Li H; Yan XG; Zhou ZW; Yi ZG; He ZX; Pan ST; Yang YX; Wang ZZ; Zhang X; Yang T; Qiu JX; Zhou SF
    Drug Des Devel Ther; 2015; 9():575-601. PubMed ID: 25632225
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.